The progress of targeted agents for HER-2 positive breast cancer
10.3969/j.issn.1000-8179.2019.18.945
- VernacularTitle:HER-2阳性乳腺癌靶向药物治疗的研究进展
- Author:
Xiaoshan CAO
1
Author Information
1. 山东第一医科大学(山东省医学科学院)
- Keywords:
breast cancer;
human epidermal growth factor receptor-2 (HER-2);
targeted agent
- From:
Chinese Journal of Clinical Oncology
2019;46(18):965-968
- CountryChina
- Language:Chinese
-
Abstract:
Human epidermal growth factor receptor-2 (HER-2) gene amplification and protein overexpression occur in approximately 15% to 20% of breast cancer patients, resulting in a clinically aggressive tumor type that is associated with a poor prognosis. HER-2-tar-geted therapies could effectively reduce the recurrence and improve the prognosis of breast cancer. In recent years, the application of new anti-HER-2 agents, such as pertuzumab, T-DM1, and pyrotinib, have further improved the survival of patients with HER2-positive breast cancer, and updated the guidelines for the treatment of breast cancer, making anti-HER-2 targeted therapy more accurate. This review described the latest development of targeted agents for HER-2-positive breast cancer.
